Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
-
April
-
May
-
June
- July -
August
-
September
-
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
- 2024
July 2024 - 55 products
IP
CI
Fluticason-Mepha 27.5 μg
120
6.87
16.70
10 %
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
CI
Vildagliptin Metformin
NOBEL 50 mg/500 mg
60
20.25
38.45
10 %
Coated tablets: 2 Active Agents
NOBEL Pharma Schweiz AG
B / SL / SG
FB
G
L
IP
CI
Vildagliptin Metformin
NOBEL 50 mg/500 mg
180
60.76
82.50
10 %
Coated tablets: 2 Active Agents
NOBEL Pharma Schweiz AG
B / SL / SG
FB
G
L
IP
Vildagliptin Metformin
NOBEL 50 mg/850 mg
60
20.25
38.45
10 %
Coated tablets: 2 Active Agents
NOBEL Pharma Schweiz AG
B / SL / SG
FB
G
L
IP
Vildagliptin Metformin
NOBEL 50 mg/850 mg
180
60.76
82.50
10 %
Coated tablets: 2 Active Agents
NOBEL Pharma Schweiz AG
B / SL / SG
FB
G
L
IP
Vildagliptin Metformin
NOBEL 50 mg/1000 mg
60
20.25
38.45
10 %
Coated tablets: 2 Active Agents
NOBEL Pharma Schweiz AG
B / SL / SG
FB
G
L
IP
Vildagliptin Metformin
NOBEL 50 mg/1000 mg
180
60.76
82.50
10 %
Coated tablets: 2 Active Agents
NOBEL Pharma Schweiz AG
B / SL / SG
FB
G
L
IP
Ximluci 10 mg/ml
481.46
544.60
10 %
Injection solution: Ranibizumabum 10 mg/ml
Spirig HealthCare AG
B / SL
FB
G
L
IP
CI
Tacrocutan 0,03%
30 g
19.60
37.75
10 %
Ointment: Tacrolimusum
Dermapharm AG
B / SL
FB
G
L
IP
CI
Tacrocutan 0,03%
60 g
34.47
53.90
10 %
Ointment: Tacrolimusum
Dermapharm AG
B / SL
FB
G
L
IP
CI
Opfolda 65 mg
24
1005.78
1110.25
10 %
Capsules: Miglustatum 65 mg
Amicus Therapeutics
Switzerland GmbH
B / SL
FB
G
L
IP
Xolair 150 mg/1.0 ml
375.83
425.15
10 %
Injektionslösung in einem Fertigpen: Omalizumabum 150 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
Xolair 300 mg/2.0 ml
751.66
833.90
10 %
Injektionslösung in einem Fertigpen: Omalizumabum 300mg / 2ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Pombiliti 105 mg
1047.63
1155.80
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Cipaglucosidasum Alfa 105 mg
Amicus Therapeutics
Switzerland GmbH
A / SL
FB
G
IP
V/S
Qdenga 0.5 ml
PR
PR
k.A.
Takeda Pharma AG
B
FB
G
IP
Sugammadex Viatris 200 mg/ 2 ml
10
PR
PR
k.A.
Injection solution: Sugammadexum 200mg / 2ml
Viatris Pharma GmbH
B
FB
G
IP
Sugammadex Viatris 500 mg/ 5 ml
10
PR
PR
k.A.
Injection solution: Sugammadexum 500mg / 5ml
Viatris Pharma GmbH
B
FB
G
IP
Tranexamic acid Leman 500
mg/5 ml
PR
PR
k.A.
Injection solution: Acidum Tranexamicum 500 mg
Leman SKL SA
B
FB
G
IP
Tranexamic acid Leman 500
mg/5 ml
5
PR
PR
k.A.
Injection solution: Acidum Tranexamicum 500 mg
Leman SKL SA
B
FB
G
IP
Tranexamic acid Leman 500
mg/5 ml
10
PR
PR
k.A.
Injection solution: Acidum Tranexamicum 500 mg
Leman SKL SA
B
FB
G
IP
Tranexamic acid Leman
1000 mg/10 ml
PR
PR
k.A.
Injection solution: Acidum Tranexamicum 1000 mg
Leman SKL SA
B
FB
G
IP
Tranexamic acid Leman
1000 mg/10 ml
5
PR
PR
k.A.
Injection solution: Acidum Tranexamicum 1000 mg
Leman SKL SA
B
FB
G
IP
Tranexamic acid Leman
1000 mg/10 ml
10
PR
PR
k.A.
Injection solution: Acidum Tranexamicum 1000 mg
Leman SKL SA
B
FB
G
IP
Ximluci 10 mg/ml
PR
PR
k.A.
Injection solution: Ranibizumabum 10 mg/ml
Spirig HealthCare AG
B
FB
G
IP
CI
Levocalm 30 mg / 5 ml
120 ml
PR
PR
k.A.
Sirup: Levodropropizinum 30mg / 5ml
Gebro Pharma AG
D
FB
G
IP
CI
Levocalm 30 mg / 5 ml
200 ml
PR
PR
k.A.
Sirup: Levodropropizinum 30mg / 5ml
Gebro Pharma AG
●
D
FB
G
Levosimendan Labatec 12.5
mg/5 ml
PR
PR
k.A.
Concentrate for infusion: Levosimendanum 12.5mg / 5ml
Labatec Pharma SA
A
FB
G
IP
Lidocain Leman
30 ml
PR
PR
k.A.
Gel: Lidocaini Hydrochloridum Anhydricum 20 mg
Leman SKL SA
B
FB
G
IP
CI
Opfolda 65 mg
4
PR
PR
k.A.
Capsules: Miglustatum 65 mg
Amicus Therapeutics
Switzerland GmbH
B
FB
G
Vitafediol 0.266 mg
5
PR
PR
k.A.
Soft capsules: Calcifediolum Monohydricum
Biomed AG
B
FB
G
Vitafediol 0.266 mg
10
PR
PR
k.A.
Soft capsules: Calcifediolum Monohydricum
Biomed AG
B
FB
G
IP
CI
Livmarli 9.5 mg/ml
30 ml
PR
PR
k.A.
Solution (oral): Maralixibatum 9.5 mg/ml
Mirum Pharmaceuticals AG
B
FB
G
Pregabalin Spirig HC 20
mg/ml
473 ml
PR
PR
k.A.
Solution (oral): Pregabalinum 20 mg/ml
Spirig HealthCare AG
B
FB
G
IP
Xolair 75 mg/0.5 ml
PR
PR
k.A.
Injektionslösung in einem Fertigpen: Omalizumabum 75mg / 0.5ml
Novartis Pharma
Schweiz AG
B
FB
G
IP
CI
Pombiliti 105 mg
10
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Cipaglucosidasum Alfa 105 mg
Amicus Therapeutics
Switzerland GmbH
A
FB
G
IP
CI
Pombiliti 105 mg
25
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Cipaglucosidasum Alfa 105 mg
Amicus Therapeutics
Switzerland GmbH
A
FB
G
IP
CI
Doxepin Rivopharm 25 mg
28
PR
PR
k.A.
capsule rigide: Doxepinum 25 mg
Rivopharm SA
B
FB
G
IP
CI
Doxepin Rivopharm 25 mg
98
PR
PR
k.A.
capsule rigide: Doxepinum 25 mg
Rivopharm SA
B
FB
G
IP
Doxepin Rivopharm 50 mg
28
PR
PR
k.A.
capsule rigide: Doxepinum 50 mg
Rivopharm SA
B
FB
G
IP
Doxepin Rivopharm 50 mg
98
PR
PR
k.A.
capsule rigide: Doxepinum 50 mg
Rivopharm SA
B
FB
G
IP
Mounjaro 2.5 mg
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 2.5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 2.5 mg
4
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 2.5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 5 mg
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 5 mg
4
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 7.5 mg
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 7.5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 7.5 mg
4
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 7.5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 10 mg
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 10mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 10 mg
4
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 10mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 12.5 mg
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 12.5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 12.5 mg
4
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 12.5mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 15 mg
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 15mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Mounjaro 15 mg
4
PR
PR
k.A.
solution for injection in vial: Tirzepatidum 15mg / 0.5ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Lidocaine Aguettant 10
mg/ml
10 x 10 ml
PR
PR
k.A.
solution injectable en seringue préremplie: Lidocaini Hydrochloridum Anhydricum 10 mg/ml
Aguettant Suisse SA
B
FB
G
IP
Lidocaine Aguettant 20
mg/ml
10 x 10 ml
PR
PR
k.A.
solution injectable en seringue préremplie: Lidocaini Hydrochloridum Anhydricum 20 mg/ml
Aguettant Suisse SA
B
FB
G
IP
Voriconazol Accord 200mg
132.94
161.00
10 %
Lyophilisate: Voriconazolum 200 mg
Accord Healthcare AG
A / SL / SG
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
